{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:55:12Z","timestamp":1788292512346,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.06.006","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T20:23:29Z","timestamp":1466454209000},"page":"4119-4122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A review of testing used in seroprevalence studies on measles and rubella"],"prefix":"10.1016","volume":"34","author":[{"given":"Wayne","family":"Dimech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mick N.","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.006_b0005","series-title":"Global measles and rubella strategic plan 2012\u20132020","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.vaccine.2016.06.006_b0010","series-title":"Global vaccine action plan: 2011\u20132020","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.vaccine.2016.06.006_b0015","unstructured":"Dimech W, Mulders MN. A 16-year review of seroprevalence studies on measles and rubella and other vaccine preventable diseases [submitted for publication]."},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2016.06.006_b0020","first-page":"S36","article-title":"The 2001 serological survey in the Czech Republic\u2013measles","volume":"11","author":"Mrazova","year":"2003","journal-title":"Cent Eur J Public Health"},{"key":"10.1016\/j.vaccine.2016.06.006_b0025","first-page":"288","article-title":"The seroprevalence of IgG antibodies against rubella (German measles) in 10\u201349 year-old women from Cartagena, Colombia","volume":"13","author":"Mora-Garcia","year":"2011","journal-title":"Rev Salud Publica (Bogota)"},{"key":"10.1016\/j.vaccine.2016.06.006_b0030","first-page":"451","article-title":"Prevalence of rubella and cytomegalovirus antibodies among pregnant women in northern Turkey","volume":"31","author":"Uyar","year":"2008","journal-title":"New Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1017\/S0950268808000848","article-title":"Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models","volume":"137","author":"Ohuma","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.06.006_b0040","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.vaccine.2008.07.005","article-title":"Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys","volume":"26","author":"Nigatu","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.006_b0045","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4269\/ajtmh.2008.79.787","article-title":"Measles-specific neutralizing antibodies in rural Mozambique: seroprevalence and presence in breast milk","volume":"79","author":"Mandomando","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.06.006_b0050","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1186\/1471-2458-13-1211","article-title":"Measles vaccination coverage estimates from surveys, clinic records, and immune markers in oral fluid and blood: a population-based cross-sectional study","volume":"13","author":"Hayford","year":"2013","journal-title":"BMC Pub Health"},{"key":"10.1016\/j.vaccine.2016.06.006_b0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10096-008-0460-3","article-title":"Detection of measles- and mumps-specific IgG antibodies in paired serum and oral fluid samples from Norwegian conscripts","volume":"27","author":"Vainio","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.006_b0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7883\/yoken.66.449","article-title":"Measles epidemiology and survey of measles immunity level among healthy population in Baoji City, Shaanxi Province, China","volume":"66","author":"Zhang","year":"2013","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.006_b0065","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.vaccine.2011.11.078","article-title":"Duration of maternally derived antibody against measles: a seroepidemiological study of infants aged under 8 months in Qinghai, China","volume":"30","author":"Zhang","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.006_b0070","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurpub\/ckm034","article-title":"Rubella immune status of indigenous and immigrant pregnant women in Catalonia, Spain","volume":"17","author":"Dominguez","year":"2007","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.vaccine.2016.06.006_b0075","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/CDLI.6.6.868-871.1999","article-title":"Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses","volume":"6","author":"Nicoara","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jviromet.2013.07.014","article-title":"Validation of an anti-measles virus-specific IgG assay with oral fluid samples for immunization surveillance in Bangladesh","volume":"193","author":"Hayford","year":"2013","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2016.06.006_b0085","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2008.08.074","article-title":"Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination","volume":"26","author":"Cohen","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.006_b0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jviromet.2005.08.001","article-title":"Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay","volume":"131","author":"Cohen","year":"2006","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2016.06.006_b0095","series-title":"Expert committee on Biological standardization: report on the collaborative study to investigate the relationship between the 1st IRP and the 2nd and 3rd international standards for anti-measles serum\/plasma in both ELISA and PRNT","author":"World Health Organization","year":"2007"},{"issue":"1","key":"10.1016\/j.vaccine.2016.06.006_b0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/CMR.00045-15","article-title":"Standardization of assays that detect anti-rubella virus IgG antibodies","volume":"29","author":"Dimech","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.vaccine.2016.06.006_b0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1128\/CVI.00603-12","article-title":"Investigation into low-level anti-rubella virus IgG results reported by commercial immunoassays","volume":"20","author":"Dimech","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0110","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/JCM.00231-08","article-title":"Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter","volume":"46","author":"Dimech","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1022567811765","article-title":"Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey","volume":"18","author":"Amela","year":"2003","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2011.11.045","article-title":"Seroprevalence of low rubella IgG antibody levels among antenatal women in England tested by NHS Blood and Transplant: 2004\u20132009. Is rubella susceptibility increasing?","volume":"30","author":"Byrne","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.006_b0125","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1590\/S0034-89102013000901080","article-title":"Seroprevalence of rubella in Colombia: a birth-year cohort analysis","volume":"47","author":"Hincapie-Palacio","year":"2013","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.vaccine.2016.06.006_b0130","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1086\/605410","article-title":"Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine","volume":"200","author":"LeBaron","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.006_b0135","doi-asserted-by":"crossref","first-page":"812","DOI":"10.26719\/2013.19.9.812","article-title":"Seroprevalence of rubella among pregnant women in Khartoum state, Sudan","volume":"19","author":"Adam","year":"2013","journal-title":"East Mediterr Health J"},{"key":"10.1016\/j.vaccine.2016.06.006_b0140","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/jmv.23195","article-title":"Rubella immune status among immigrant and nonimmigrant women in Spain","volume":"84","author":"Ramos","year":"2012","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/adc.67.1_Spec_No.41","article-title":"IgG subclasses compared in maternal and cord serum and breast milk","volume":"67","author":"Gasparoni","year":"1992","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2016.06.006_b0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jviromet.2004.09.001","article-title":"Detection of HCV antibodies in oral fluid","volume":"122","author":"De Cock","year":"2004","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2016.06.006_b0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0166-0934(97)02210-6","article-title":"An evaluation of nine commercial EIA kits for the detection of measles specific IgG","volume":"66","author":"Hesketh","year":"1997","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2016.06.006_b0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2015.11.022","article-title":"Performance of 14 rubella IgG immunoassays on samples with low positive or negative haemagglutination inhibition results","volume":"74","author":"Huzly","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0165","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/S0264-410X(00)00139-0","article-title":"Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland","volume":"18","author":"Davidkin","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.006_b0170","first-page":"287","article-title":"Seroprevalence of rubella IgG antibody in pregnant women in osogbo, Nigeria","volume":"5","author":"Kolawole","year":"2014","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.vaccine.2016.06.006_b0175","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","article-title":"Measles antibody: reevaluation of protective titers","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.006_b0180","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2008.06.028","article-title":"ELISA underestimates measles antibody seroprevalence in US military recruits","volume":"26","author":"Mancuso","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.006_b0185","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcv.2015.06.095","article-title":"Immune status of health care workers to measles virus: evaluation of protective titers in four measles IgG EIAs","volume":"69","author":"Dorigo-Zetsma","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2016.06.006_b0190","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/infdis\/172.6.1591","article-title":"Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination","volume":"172","author":"Ward","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.006_b0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1017\/S0950268899004173","article-title":"The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella","volume":"125","author":"Andrews","year":"2000","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.06.006_b0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2807\/esm.09.04.00456-en","article-title":"Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2)","volume":"9","author":"Nardone","year":"2004","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.06.006_b0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2807\/esm.02.04.00167-en","article-title":"The European sero-epidemiology network","volume":"2","author":"Osborne","year":"1997","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.06.006_b0210","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1017\/S095026881400301X","article-title":"Estimating seroprevalence of vaccine-preventable infections: is it worth standardizing the serological outcomes to adjust for different assays and laboratories?","volume":"143","author":"Kafatos","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.06.006_b0215","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1515\/cclm-2014-0546","article-title":"Determination of quality control limits for serological infectious disease testing using historical data","volume":"53","author":"Dimech","year":"2015","journal-title":"Clin Chem Lab Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T17:23:52Z","timestamp":1600795432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16304054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":43,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16304054"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of testing used in seroprevalence studies on measles and rubella","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}